Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19-chimeric Antigen Receptor T Cells”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)UnknownNCT04486872
What this trial is testing

An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

Who this might be right for
Diffuse Large B Cell Lymphoma
First Affiliated Hospital of Zhejiang University 18
Early research (Phase 1)UnknownNCT03559439
What this trial is testing

CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies

Who this might be right for
B-cell MalignancyB-cell LymphomaB-Cell Acute Lymphoblastic Leukaemia
Shanghai Tong Ren Hospital 9
Early research (Phase 1)Study completedNCT06027957
What this trial is testing

CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

Who this might be right for
B-Cell Non Hodgkin LymphomaB-Cell Acute Lymphoblastic Leukemia
Vinmec Research Institute of Stem Cell and Gene Technology 18
Very early researchUnknownNCT05225831
What this trial is testing

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
CD19+ and CD 22+ B-ALL
Hebei Senlang Biotechnology Inc., Ltd. 100
Early research (Phase 1)Looking for participantsNCT06752785
What this trial is testing

CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.

Who this might be right for
Acute Lymphoblastic Leukemia
Guangzhou Women and Children's Medical Center 10
Very early researchUnknownNCT06393335
What this trial is testing

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Who this might be right for
Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma
The Children's Hospital of Zhejiang University School of Medicine 36
Early research (Phase 1)Looking for participantsNCT07031713
What this trial is testing

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE

Who this might be right for
Systemic Lupus Erythematosus (SLE)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 12
Large-scale testing (Phase 3)Looking for participantsNCT07502118
What this trial is testing

NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)Relapsed/Refractory Non-Hodgkin LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)+2 more
Health Institutes of Turkey 40
Early research (Phase 1)Looking for participantsNCT07369492
What this trial is testing

Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma

Who this might be right for
B-cell Lymphoma
Jiangsu Topcel-KH Pharmaceutical Co., Ltd. 30
Early research (Phase 1)Study completedNCT03483688
What this trial is testing

A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

Who this might be right for
B-cell Non-Hodgkin Lymphoma
Peking Union Medical College Hospital 6
Early research (Phase 1)Looking for participantsNCT06569472
What this trial is testing

Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis

Who this might be right for
Juvenile Dermatomyositis
Chongqing Precision Biotech Co., Ltd 10
Early research (Phase 1)Active Not RecruitingNCT01860937
What this trial is testing

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
Relapsed B-Cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center 23
Testing effectiveness (Phase 2)Looking for participantsNCT07587840
What this trial is testing

CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma

Who this might be right for
Lymphoma
Liping Dou 20
Early research (Phase 1)Looking for participantsNCT06710717
What this trial is testing

Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)

Who this might be right for
Systemic Lupus Erythematous (SLE)
National University of Malaysia 5
Early research (Phase 1)Active Not RecruitingNCT05081479
What this trial is testing

N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma

Who this might be right for
Lymphoma
Memorial Sloan Kettering Cancer Center 9
Testing effectiveness (Phase 2)WithdrawnNCT03098355
What this trial is testing

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

Who this might be right for
B-Cell LeukemiaB-Cell Lymphoma
Zhujiang Hospital
Testing effectiveness (Phase 2)UnknownNCT03166878
What this trial is testing

A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

Who this might be right for
B Cell LeukemiaB Cell Lymphoma
Chinese PLA General Hospital 80
Early research (Phase 1)Not Yet RecruitingNCT07114432
What this trial is testing

RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma

Who this might be right for
Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCTNewly Diagnosed Multiple Myeloma (NDMM)
Tianjin Medical University Cancer Institute and Hospital 19
Very early researchUnknownNCT04617704
What this trial is testing

BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 15
Early research (Phase 1)Looking for participantsNCT07315087
What this trial is testing

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

Who this might be right for
SLE - Systemic Lupus ErythematosusSSc-Systemic SclerosisIIM- Idiopathic Inflammatory Myopathies+3 more
Institute of Hematology & Blood Diseases Hospital, China 12
Next Page